Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
Edward J Meier,1 Gail L Torkildsen,2 Paul J Gomes,3 Mark C Jasek4 1Apex Eye, Mason, OH, USA; 2Andover Eye, Andover, MA, USA; 3Allergy, Ora, Inc., Andover, MA, USA; 4Eyevance Pharmaceuticals, TX, USA Purpose: The purpose of these Phase III studies was to evaluate the efficacy and safety of cetirizi...
Guardado en:
Autores principales: | Meier EJ, Torkildsen GL, Gomes PJ, Jasek MC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dd456f467fde4c778cdab3f61ac7aca1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019) -
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin E, et al.
Publicado: (2017) -
Application of diphenydramine ointment to the eyelids for allergic conjunctivitis
por: Mitsuhiro Kamimura, et al.
Publicado: (2021) -
A Review of the Differential Diagnosis of Acute Infectious Conjunctivitis: Implications for Treatment and Management
por: Yeu E, et al.
Publicado: (2020) -
Evaluation of The Role of Topical Cetirizine 1% in Treatment of Male Androgenetic Alopecia
por: Hebat-Allah Elsherbeny, et al.
Publicado: (2020)